Reports
Reports
Therapeutics such as corticosteroids are being extensively used as joint injections for horses. Bisphosphonates such as tiludronate disodium (Tildren) and clondronate (Osphos) are labeled for controlling clinical signs associated with navicular syndrome. There is a need for research surrounding bisphosphonate’s use in horses under the age of four.
As such, the equine healthcare market is riding on increasing awareness about the importance of horses’ health.
The global equine healthcare market is expected to grow owing to the rise in equine population due to increasing frequency of horse ownership, sports, and recreational activities. Moreover, growing demand for preventive care including vaccinations, deworming, and regular check-ups is expected to foster the overall market growth in the upcoming future. Furthermore, the equine healthcare industry growth is primarily fueled by the rising population of domesticated and sport horses globally. As equestrian sports continue to gain popularity-ranging from horse racing and dressage to endurance and rodeo-there is growing demand for high-quality veterinary care.
| Attribute | Detail |
|---|---|
| Equine Healthcare Market Drivers |
|
The increased prevalence of equine diseases is a key driving force of the equine healthcare market, affecting many segments of the market and leading to rising demand for various products and services. Rising incidence of equine diseases can increase the rate of awareness among horse owners and veterinarians regarding the need for preventive care. This ranges from routine vaccinations, deworming programs, and check-ups.
For example, equine influenza, equine herpesvirus (EHV), and West Nile virus are a few infectious diseases on the rise. Due to this, there is an increasing demand for vaccines against the infections that are potent enough to provide protection to horses against diseases. Likewise, the pressure of internal and external parasites is propelling the demand for effective parasiticides and deworming.
Regular deworming programs are crucial in maintaining the health and functioning of horses and, consequently, increase the market for parasiticides. Disease detection at early stages is an important consideration in equine health care. There is an increase in frequency of more advanced diagnostic tests, such as blood tests, imaging (X-Ray, ultrasound, MRI, and CT scans), and genetic tests.
Health check-ups are more commonly employed by horse owners and veterinarians to keep track of the general health of horses and pick out potential underlying conditions early. Early diagnosis can result in enhanced and less expensive treatment, maximizing long-term horse health and productivity. This is fueling growth in the diagnostic portion of the equine healthcare market.
The rise in incidence of disease is also increasing demand for therapeutic medicine. This comprises a wide range of drugs like antibiotics, anti-inflammatory, and analgesics. Occurrences if diseases like lameness, respiratory disease, and gastrointestinal disease are on the rise, and there is an increasing need for effective medicine. There is also specialized medicine for diseases like equine metabolic syndrome, laminitis, and equine Cushing's.
R&D activities have developed more effective and efficient parasiticides, anti-infectives, and anti-inflammatory chemical species-specific that are less toxic for long-term administration. Slow-release drug and advanced anthelmintics are a few examples, which are more effectively controlling internal parasites with negligible resistance.
Veterinary R&D activities have introduced high-technology imaging and diagnostic modalities like digital radiography, ultrasound, and endoscopy for early diagnosis of musculoskeletal, respiratory, and reproductive disease of horses. The technology enhances treatment efficacy and reduces competition horse downtime. Regenerative medicine–stem cell therapy, platelet-rich plasma (PRP), and prolotherapy technology are revolutionizing equine medicine, particularly joint trauma, tendon/ligament injury, and osteoarthritis care.
The biologic therapies promote healing of performance animals and become increasingly available through research. Genetic diagnosis, biomarker identification, and individualized health planning are being enabled by research and development activities for horses. Accuracy testing is facilitating early disease diagnosis of genetic disease, enhanced breeding results, and lifetime health.
The therapeutics industry in the equine health sector is controlled by the therapeutics segment due to the prevalence of the major equine diseases and the focal role of drugs in general veterinary practice. The equine animals are prone to numerous forms of diseases like respiratory infections, gastrointestinal disease, arthritic inflammation, and parasitic disease that have to be treated and cured by continuous drug therapy. Therefore, gastrointestinal medications, anti-infectives, and anti-inflammatory drugs are never in short supply, and therapeutics become a routine part of normal equine care.
The most significant aspect of this ubiquity is the rampant use of parasiticides. Deworming is a fundamental part of equine husbandry, especially in breeding and agricultural operations where parasites are managed due to their necessity to be maintained under control for herd well-being. With growing resistance to the traditional deworming medicines, demand for good and safe parasiticides is even higher.
Anti-inflammatories and analgesics are also administered regularly to race-oriented horses to cure lameness and arthritis so that they can recover faster and compete on equal terms. Furthermore, developments in veterinary pharmaceuticals and medicines have augmented the arsenal of treatments.
Targeted therapies, long-acting injectables, and regenerative medications such as stem cell treatment and platelet-rich plasma (PRP) are being consumed in huge volumes, most notably on premium horses such as racehorses and showjumpers. The innovations are introducing efficacy and appeal to therapeutics, thus inducing greater uptake among both - the developed nations and emerging countries.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America, and the United States above all, holds the largest equine healthcare market share due to a series of healthy health policy decisions, high level of awareness, buying power, and common availability. Additionally, North American consumers place high importance on convenience, cleanliness, and technology, and hence the market is open to high-end and innovative products.
Leading companies are partnering with hospitals, specialty clinics, and research institutes to expand inorganically. Zoetis, Arthrex, Inc., Dechra Pharmaceuticals, Boehringer Ingelheim, Animal Health USA Inc., Ceva, Heska Corporation, Merck & Co., Inc., Esaote SpA, IDEXX, Covetrus, Elanco, Cargill Incorporated, Santa Cruz Biotechnology Inc. are the prominent equine healthcare market players.
Each of these players has been have been profiled in the equine healthcare industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 0.8 Bn |
| Forecast Value in 2035 | US$ 1.3 Bn |
| CAGR | 4.8% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global equine healthcare market was valued at US$ 0.8 Bn in 2024.
Equine Healthcare business is projected to cross US$ 1.3 Bn by the end of 2035.
Growing incidence of equine diseases and rising research and development across the veterinary field.
The CAGR is anticipated to be 4.8% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
Zoetis, Arthrex, Inc., Dechra Pharmaceuticals, Boehringer Ingelheim, Animal Health USA Inc., Ceva, Heska Corporation, Merck & Co., Inc., Esaote SpA, IDEXX, Covetrus, Elanco, Cargill Incorporated, Santa Cruz Biotechnology Inc, and other players are the prominent Equine Healthcare Market players.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Equine Healthcare Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Equine Healthcare Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Equine Healthcare Market Trends
5.2. Regulatory Scenario Across Key Regions/Countries
5.3. PESTEL Analysis
5.4. PORTER's Analysis
5.5. Pipeline Analysis for Equine Drugs and Vaccines
5.6. Pricing Trends of Equine Health Care Products
5.7. Key Industry Events
5.8. Epidemiology Analysis Across Key Regions/Countries
5.9. Go-to-Market Strategy for New Market Entrants
5.10. Key Shortlisting Metrics for End-users
5.11. Benchmarking of the Products Offered by the Leading Competitors
6. Global Equine Healthcare Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2020 to 2035
6.3.1. Therapeutics
6.3.1.1. Drugs
6.3.1.1.1. Anti-Infective
6.3.1.1.2. Anti-inflammatory
6.3.1.1.3. Parasiticides
6.3.1.1.4. Others
6.3.1.2. Vaccine
6.3.1.2.1. Inactivated
6.3.1.2.2. Live Attenuated
6.3.1.2.3. Recombinant
6.3.1.2.4. Others
6.3.1.3. Supplemental Feed additives
6.3.1.3.1. Proteins and amino acids
6.3.1.3.2. Vitamins
6.3.1.3.3. Enzymes
6.3.1.3.4. Minerals
6.3.1.3.5. Others
6.3.1.4. Regenerative Medicine
6.3.2. Diagnostics
6.3.2.1. Diagnostic Kits & Reagents
6.3.2.2. Instruments
6.4. Market Attractiveness By Product Type
7. Global Equine Healthcare Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2020 to 2035
7.3.1. Equine Influenza
7.3.2. Equine Herpes virus (EHV)
7.3.3. Equine Encephalomyelitis
7.3.4. West Nile Virus
7.3.5. Equine Rabies
7.3.6. Potomac Horse Fever
7.3.7. Osteoarthritis
7.3.8. Tetanus
7.3.9. Others
7.4. Market Attractiveness By Indication
8. Global Equine Healthcare Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020 to 2035
8.3.1. Veterinary Hospitals
8.3.2. Equine Clinics
8.3.3. Equestrian Facilities
8.3.4. Others
8.4. Market Attractiveness By End-user
9. Global Equine Healthcare Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Equine Healthcare Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product Type, 2020 to 2035
10.2.1. Therapeutics
10.2.1.1. Drugs
10.2.1.1.1. Anti-Infective
10.2.1.1.2. Anti-inflammatory
10.2.1.1.3. Parasiticides
10.2.1.1.4. Others
10.2.1.2. Vaccine
10.2.1.2.1. Inactivated
10.2.1.2.2. Live Attenuated
10.2.1.2.3. Recombinant
10.2.1.2.4. Others
10.2.1.3. Supplemental Feed additives
10.2.1.3.1. Proteins and amino acids
10.2.1.3.2. Vitamins
10.2.1.3.3. Enzymes
10.2.1.3.4. Minerals
10.2.1.3.5. Others
10.2.1.4. Regenerative Medicine
10.2.2. Diagnostics
10.2.2.1. Diagnostic Kits & Reagents
10.2.2.2. Instruments
10.3. Market Value Forecast By Indication, 2020 to 2035
10.3.1. Equine Influenza
10.3.2. Equine Herpes virus (EHV)
10.3.3. Equine Encephalomyelitis
10.3.4. West Nile Virus
10.3.5. Equine Rabies
10.3.6. Potomac Horse Fever
10.3.7. Osteoarthritis
10.3.8. Tetanus
10.3.9. Others
10.4. Market Value Forecast By End-user, 2020 to 2035
10.4.1. Veterinary Hospitals
10.4.2. Equine Clinics
10.4.3. Equestrian Facilities
10.4.4. Others
10.5. Market Value Forecast By Country, 2020 to 2035
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Equine Healthcare Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product Type, 2020 to 2035
11.2.1. Therapeutics
11.2.1.1. Drugs
11.2.1.1.1. Anti-Infective
11.2.1.1.2. Anti-inflammatory
11.2.1.1.3. Parasiticides
11.2.1.1.4. Others
11.2.1.2. Vaccine
11.2.1.2.1. Inactivated
11.2.1.2.2. Live Attenuated
11.2.1.2.3. Recombinant
11.2.1.2.4. Others
11.2.1.3. Supplemental Feed additives
11.2.1.3.1. Proteins and amino acids
11.2.1.3.2. Vitamins
11.2.1.3.3. Enzymes
11.2.1.3.4. Minerals
11.2.1.3.5. Others
11.2.1.4. Regenerative Medicine
11.2.2. Diagnostics
11.2.2.1. Diagnostic Kits & Reagents
11.2.2.2. Instruments
11.3. Market Value Forecast By Indication, 2020 to 2035
11.3.1. Equine Influenza
11.3.2. Equine Herpes virus (EHV)
11.3.3. Equine Encephalomyelitis
11.3.4. West Nile Virus
11.3.5. Equine Rabies
11.3.6. Potomac Horse Fever
11.3.7. Osteoarthritis
11.3.8. Tetanus
11.3.9. Others
11.4. Market Value Forecast By End-user, 2020 to 2035
11.4.1. Veterinary Hospitals
11.4.2. Equine Clinics
11.4.3. Equestrian Facilities
11.4.4. Others
11.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Switzerland
11.5.7. The Netherlands
11.5.8. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Equine Healthcare Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product Type, 2020 to 2035
12.2.1. Therapeutics
12.2.1.1. Drugs
12.2.1.1.1. Anti-Infective
12.2.1.1.2. Anti-inflammatory
12.2.1.1.3. Parasiticides
12.2.1.1.4. Others
12.2.1.2. Vaccine
12.2.1.2.1. Inactivated
12.2.1.2.2. Live Attenuated
12.2.1.2.3. Recombinant
12.2.1.2.4. Others
12.2.1.3. Supplemental Feed additives
12.2.1.3.1. Proteins and amino acids
12.2.1.3.2. Vitamins
12.2.1.3.3. Enzymes
12.2.1.3.4. Minerals
12.2.1.3.5. Others
12.2.1.4. Regenerative Medicine
12.2.2. Diagnostics
12.2.2.1. Diagnostic Kits & Reagents
12.2.2.2. Instruments
12.3. Market Value Forecast By Indication, 2020 to 2035
12.3.1. Equine Influenza
12.3.2. Equine Herpes virus (EHV)
12.3.3. Equine Encephalomyelitis
12.3.4. West Nile Virus
12.3.5. Equine Rabies
12.3.6. Potomac Horse Fever
12.3.7. Osteoarthritis
12.3.8. Tetanus
12.3.9. Others
12.4. Market Value Forecast By End-user, 2020 to 2035
12.4.1. Veterinary Hospitals
12.4.2. Equine Clinics
12.4.3. Equestrian Facilities
12.4.4. Others
12.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. South Korea
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Equine Healthcare Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2020 to 2035
13.2.1. Therapeutics
13.2.1.1. Drugs
13.2.1.1.1. Anti-Infective
13.2.1.1.2. Anti-inflammatory
13.2.1.1.3. Parasiticides
13.2.1.1.4. Others
13.2.1.2. Vaccine
13.2.1.2.1. Inactivated
13.2.1.2.2. Live Attenuated
13.2.1.2.3. Recombinant
13.2.1.2.4. Others
13.2.1.3. Supplemental Feed additives
13.2.1.3.1. Proteins and amino acids
13.2.1.3.2. Vitamins
13.2.1.3.3. Enzymes
13.2.1.3.4. Minerals
13.2.1.3.5. Others
13.2.1.4. Regenerative Medicine
13.2.2. Diagnostics
13.2.2.1. Diagnostic Kits & Reagents
13.2.2.2. Instruments
13.3. Market Value Forecast By Indication, 2020 to 2035
13.3.1. Equine Influenza
13.3.2. Equine Herpes virus (EHV)
13.3.3. Equine Encephalomyelitis
13.3.4. West Nile Virus
13.3.5. Equine Rabies
13.3.6. Potomac Horse Fever
13.3.7. Osteoarthritis
13.3.8. Tetanus
13.3.9. Others
13.4. Market Value Forecast By End-user, 2020 to 2035
13.4.1. Veterinary Hospitals
13.4.2. Equine Clinics
13.4.3. Equestrian Facilities
13.4.4. Others
13.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Equine Healthcare Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2020 to 2035
14.2.1. Therapeutics
14.2.1.1. Drugs
14.2.1.1.1. Anti-Infective
14.2.1.1.2. Anti-inflammatory
14.2.1.1.3. Parasiticides
14.2.1.1.4. Others
14.2.1.2. Vaccine
14.2.1.2.1. Inactivated
14.2.1.2.2. Live Attenuated
14.2.1.2.3. Recombinant
14.2.1.2.4. Others
14.2.1.3. Supplemental Feed additives
14.2.1.3.1. Proteins and amino acids
14.2.1.3.2. Vitamins
14.2.1.3.3. Enzymes
14.2.1.3.4. Minerals
14.2.1.3.5. Others
14.2.1.4. Regenerative Medicine
14.2.2. Diagnostics
14.2.2.1. Diagnostic Kits & Reagents
14.2.2.2. Instruments
14.3. Market Value Forecast By Indication, 2020 to 2035
14.3.1. Equine Influenza
14.3.2. Equine Herpes virus (EHV)
14.3.3. Equine Encephalomyelitis
14.3.4. West Nile Virus
14.3.5. Equine Rabies
14.3.6. Potomac Horse Fever
14.3.7. Osteoarthritis
14.3.8. Tetanus
14.3.9. Others
14.4. Market Value Forecast By End-user, 2020 to 2035
14.4.1. Veterinary Hospitals
14.4.2. Equine Clinics
14.4.3. Equestrian Facilities
14.4.4. Others
14.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Indication
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2024)
15.3. Company Profiles
15.3.1. Zoetis
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Financial Overview
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Arthrex, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Financial Overview
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Dechra Pharmaceuticals
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Financial Overview
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Boehringer Ingelheim Animal Health USA Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Financial Overview
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Ceva
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Financial Overview
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Heska Corporation
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Financial Overview
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Merck & Co., Inc.,
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Financial Overview
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Esaote SpA
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Financial Overview
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. IDEXX
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Financial Overview
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Covetrus
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Financial Overview
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
15.3.11. Elanco
15.3.11.1. Company Overview
15.3.11.2. Financial Overview
15.3.11.3. Financial Overview
15.3.11.4. Business Strategies
15.3.11.5. Recent Developments
15.3.12. Cargill, Incorporated
15.3.12.1. Company Overview
15.3.12.2. Financial Overview
15.3.12.3. Financial Overview
15.3.12.4. Business Strategies
15.3.12.5. Recent Developments
15.3.13. Santa Cruz Biotechnology Inc.
15.3.13.1. Company Overview
15.3.13.2. Financial Overview
15.3.13.3. Financial Overview
15.3.13.4. Business Strategies
15.3.13.5. Recent Developments
15.3.14. Other Prominent Players
15.3.14.1. Company Overview
15.3.14.2. Financial Overview
15.3.14.3. Financial Overview
15.3.14.4. Business Strategies
15.3.14.5. Recent Developments
List of Tables
Table 01: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Product Type, 2020 to 2035
Table 02: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 03: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 04: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 05: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 06: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 07: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Indication, 2020 to 2035
Table 08: Global Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 09: Global Equine Healthcare Market Value (US$ Mn) Forecast, By Region, 2020 to 2035
Table 10: North America - Equine Healthcare Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 11: North America - Equine Healthcare Market Value (US$ Mn) Forecast, by Product Type, 2020 to 2035
Table 12: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 13: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 14: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 15: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 16: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 17: North America - Equine Healthcare Market Value (US$ Mn) Forecast, by Indication, 2020 to 2035
Table 18: North America - Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 19: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 20: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, by Product Type, 2020 to 2035
Table 21: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 22: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 23: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 24: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 25: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 26: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, by Indication, 2020 to 2035
Table 27: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 28: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 29: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, by Product Type, 2020 to 2035
Table 30: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 31: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 32: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 33: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 34: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 35: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, by Indication, 2020 to 2035
Table 36: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 37: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 38: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, by Product Type, 2020 to 2035
Table 39: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 40: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 41: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 42: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 43: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 44: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, by Indication, 2020 to 2035
Table 45: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 46: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 47: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, by Product Type, 2020 to 2035
Table 48: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By Therapeutics, 2020 to 2035
Table 49: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By Drugs, 2020 to 2035
Table 50: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By Vaccine, 2020 to 2035
Table 51: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By Supplemental Feed Additives, 2020 to 2035
Table 52: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By Diagnostics, 2020 to 2035
Table 53: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, by Indication, 2020 to 2035
Table 54: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
List of Figures
Figure 01: Global Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 02: Global Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 03: Global Equine Healthcare Market Revenue (US$ Mn), by Therapeutics, 2020 to 2035
Figure 04: Global Equine Healthcare Market Revenue (US$ Mn), by Diagnostics, 2020 to 2035
Figure 05: Global Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 06: Global Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 07: Global Equine Healthcare Market Revenue (US$ Mn), by Equine Influenza, 2020 to 2035
Figure 08: Global Equine Healthcare Market Revenue (US$ Mn), by Equine Herpes virus (EHV), 2020 to 2035
Figure 09: Global Equine Healthcare Market Revenue (US$ Mn), by Equine Encephalomyelitis, 2020 to 2035
Figure 10: Global Equine Healthcare Market Revenue (US$ Mn), by West Nile Virus, 2020 to 2035
Figure 11: Global Equine Healthcare Market Revenue (US$ Mn), by Equine Rabies, 2020 to 2035
Figure 12: Global Equine Healthcare Market Revenue (US$ Mn), by Potomac Horse Fever, 2020 to 2035
Figure 13: Global Equine Healthcare Market Revenue (US$ Mn), by Osteoarthritis, 2020 to 2035
Figure 14: Global Equine Healthcare Market Revenue (US$ Mn), by Tetanus, 2020 to 2035
Figure 15: Global Equine Healthcare Market Revenue (US$ Mn), by Others, 2020 to 2035
Figure 16: Global Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 17: Global Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 18: Global Equine Healthcare Market Revenue (US$ Mn), by Veterinary Hospitals, 2020 to 2035
Figure 19: Global Equine Healthcare Market Revenue (US$ Mn), by Equine Clinics, 2020 to 2035
Figure 20: Global Equine Healthcare Market Revenue (US$ Mn), by Equestrian Facilities, 2020 to 2035
Figure 21: Global Equine Healthcare Market Revenue (US$ Mn), by Others, 2020 to 2035
Figure 22: Global Equine Healthcare Market Value Share Analysis, By Region, 2024 and 2035
Figure 23: Global Equine Healthcare Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 24: North America - Equine Healthcare Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 25: North America - Equine Healthcare Market Value Share Analysis, by Country, 2024 and 2035
Figure 26: North America - Equine Healthcare Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 27: North America Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 28: North America Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 29: North America - Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 30: North America - Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 31: North America - Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 32: North America - Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 33: Europe - Equine Healthcare Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 34: Europe - Equine Healthcare Market Value Share Analysis, by Country, 2024 and 2035
Figure 35: Europe - Equine Healthcare Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 36: Europe Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 37: Europe Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 38: Europe - Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 39: Europe - Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 40: Europe - Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 41: Europe - Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 42: Asia Pacific - Equine Healthcare Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 43: Asia Pacific - Equine Healthcare Market Value Share Analysis, by Country, 2024 and 2035
Figure 44: Asia Pacific - Equine Healthcare Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 45: Asia Pacific Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 46: Asia Pacific Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 47: Asia Pacific - Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 48: Asia Pacific - Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 49: Asia Pacific - Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 50: Asia Pacific - Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 51: Latin America - Equine Healthcare Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 52: Latin America - Equine Healthcare Market Value Share Analysis, by Country, 2024 and 2035
Figure 53: Latin America - Equine Healthcare Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 54: Latin America Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 55: Latin America Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 56: Latin America - Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 57: Latin America - Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 58: Latin America - Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 59: Latin America - Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 60: Middle East & Africa - Equine Healthcare Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 61: Middle East & Africa - Equine Healthcare Market Value Share Analysis, by Country, 2024 and 2035
Figure 62: Middle East & Africa - Equine Healthcare Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 63: Middle East & Africa Equine Healthcare Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 64: Middle East & Africa Equine Healthcare Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 65: Middle East & Africa - Equine Healthcare Market Value Share Analysis, By Indication, 2024 and 2035
Figure 66: Middle East & Africa - Equine Healthcare Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 67: Middle East & Africa - Equine Healthcare Market Value Share Analysis, By End-user, 2024 and 2035
Figure 68: Middle East & Africa - Equine Healthcare Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Equine Healthcare Market